ID
34016
Description
Study ID: 103974 (primary study) Clinical Study ID: 103974 Study Title: Demonstrate non-inferiority of Men-C immune response of Hib-MenC with Infanrix™-IPV versus a licensed Men-C vaccine with Pediacel™ when given at 2, 3, 4 months and the immunogenicity of Hib-MenC when given as a booster dose at 12-15 months Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00258700 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: Haemophilus influenzae Type b, Meningococcal C-Tetanus Toxoid Conjugate Vaccine Trade Name: BIO HIB-MENC-TT; Menitorix Study Indication: Haemophilus influenzae type b; Neisseria Meningitidis
Mots-clés
Versions (1)
- 11/01/2019 11/01/2019 -
Détendeur de droits
GSK group of companies
Téléchargé le
11 janvier 2019
DOI
Pour une demande vous connecter.
Licence
Creative Commons BY-NC 3.0
Modèle Commentaires :
Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.
Groupe Item commentaires pour :
Item commentaires pour :
Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.
Primary & Booster Immunogenicity of Hib-MenC vs a Licensed Men-C Vaccine - 103974
Visit 6: Eligibility Check, Laboratory Test
- StudyEvent: ODM
Description
Check for Study Continuation
Description
Did the subject return for Visit 6?
Type de données
boolean
Description
If No, please tick ONE most appropriate reason
Type de données
text
Description
If Other, please specify
Type de données
text
Description
If SAE, record the SAE number
Type de données
integer
Description
If non-SAE, please record the AE number
Type de données
integer
Description
Please tick who took the decision
Type de données
text
Description
Elimination Criteria During The Study
Description
If any of the criteria become applicable during the study, it will not require withdrawal of the subject from the study but may determine a subject's evaluability in the according-to-protocol (ATP) analysis.
Type de données
text
Description
1. Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) during the study period
Type de données
text
Description
2. Chronic administration (defined as more than 14 days) or immunodepressants or other imminodefying drugs during the study period.
Type de données
text
Description
3. Administration of a vaccine not foreseen by the study protocol during the period starting from 30 days before each dose of vaccine(s) and ending 30 days after
Type de données
text
Description
4. Administration of immunoglobulins and/or any blood products during the study period
Type de données
text
Description
Laboratory Tests - Blood
Similar models
Visit 6: Eligibility Check, Laboratory Test
- StudyEvent: ODM
Aucun commentaire